A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

Recruiting now. Registry record last updated August 31, 2026.

Who can join: Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.
What you take: Pemvidutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 6 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor Altimmune, Inc.Drug pemvidutideClass GLP-1/glucagonSites 9 USEnrollment target 1,800

What this study is for

Primary condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Full scientific study title: Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH.

Who can join

Age18 to 75SexAnyBMI23 or higher

Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
Subject agrees to have liver biopsy(ies) as required per protocol

Key exclusion criteria

Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
Uncontrolled T2D or clinically significant persistent hyperglycemia

Where this trial is enrolling

This trial has 9 sites across 4 states. Contact a site coordinator directly to start screening.

Find a site near you

Arkansas1 site

Altimmune Clinical Study Site
North Little Rock, Arkansas

California4 sites

Altimmune Clinical Study Site
Fountain Valley, California
Altimmune Clinical Study Site
Fresno, California
Altimmune Clinical Study Site
Gardena, California
Altimmune Clinical Study Site
Long Beach, California

Florida2 sites

Altimmune Clinical Study Site
Miami, Florida
Altimmune Clinical Study Site
Ocala, Florida

Ohio2 sites

Altimmune Clinical Study Site
Springboro, Ohio
Altimmune Clinical Study Site
Westlake, Ohio

Follow this trial

We email you if NCT07795164 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: July 30, 2026. Expected completion: December 2032. Last updated on ClinicalTrials.gov: August 31, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.